As you probably know there is a devastating Marburg (Marburg is a cousin of the Ebola virus) epidemic in Angola right now. Look at what one American company is doing to make a buck.

This American Co. sounds to me like snake oil peddlers (look at the list of diseases they claim their viral antidote helps) & opportunists that are willing to take advantage of peoples fears so that they can make a buck by doing human experimentation. I checked out their annual report and they don't sound like they are doing very well. They even claim that if they can not get enough people signed up for their clinical trials that they may have to declare bankruptcy. Take a look at their annual report that I have posted here to see who they are targeting. I could not find a list of major investors in this company. If anyone can find them I sure would be interested.

You can also check out the exerpt that I posted after this article. This exerpt comes from a NYT article.

GenoMed launches free trial against Marburg virus epidemic in Angola
Disease/Infection News
Published: Tuesday, 26-Apr-2005

GenoMed announced today that it has launched a free clinical trial to combat the current Marburg virus epidemic in Angola.
Marburg virus causes a hemorrhagic fever which is fatal in 80% of cases. The current epidemic, the largest in history, began in the northern province of Uige in Angola in early March. It has since spread throughout much of Angola. So far, over 240 people have died, many of them children, and another 264 people are currently infected.

Marburg virus is considered a prime candidate for use by viral bioterrorists.

GenoMed believes it has a broad-spectrum viral antidote, which it has been testing successfully against West Nile virus for the past two summers. It should work equally well against influenza, avian influenza, SARS, respiratory syncytial virus (RSV) in children, and the common cold. It may also be effective against HIV and tuberculosis (Tb). Tb, of course, is caused by the tubercle bacillus, a kind of bacteria.

Said Dr. David Moskowitz, Chief Medical & Executive Officer for GenoMed, "Our positive experience so far with West Nile virus encephalitis gives us hope that our approach will be successful against other lethal viruses like Marburg virus. We're grateful to Angola for allowing us to try to help during the current awful epidemic."

Dr. Moskowitz went on to say, "The Internet now makes it possible for anybody to enroll in our free clinical trial at any time of day or night anywhere in the world, simply by going to our website and clicking on the link for the trial. People will have to enter their email address so that we can follow up with them and eventually publish our results. In return for their email address, they'll be able to download the documents they'll need to show their physician in order to get started immediately on our trial. A family member could easily do this for a child who is sick. The drugs we use are available in every drug store around the world."

http://www.genomed.com


http://www.news-medical.net/?id=9521



I'm going to call the WHO tomorrow and see what they can tell me about these charlatans. If what I suspect is true, these people should be driven out of Angola.:

If you are interested in reading more about the epidemic of this lethal disease in Angola click here

http://www.commongroundcommonsense.org/for...showtopic=24648

Board of Directors


David W. Moskowitz, MD- Chairman, Chief Executive Officer, and Chief Medical Officer
Richard A. Kranitz, J.D. - Corporate Secretary and Board Member
David W. Moskowitz, MD- Chairman, Chief Executive Officer, and Chief Medical Officer
Dr. Moskowitz majored in Chemistry (summa cum laude) at Harvard College, Biochemistry (first class honours) at Merton College, Oxford, and received an MD (cum laude) from the Harvard-MIT Division in Health Sciences and Technology (Harvard Medical School). He trained for 7 years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. Since 1994, Dr. Moskowitz has experienced first hand the clinical effectiveness of knowing a disease-associated gene (the angiotensin converting enzyme, or ACE, gene). Dr. Moskowitz is a pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes.

Back to top

Richard A. Kranitz, J.D. - Corporate Secretary and Board Member
Richard Kranitz has been an attorney in private practice since 1970, with an emphasis in securities, banking and business law. He is a 1969 graduate of the University of Wisconsin Law School and served for a year as an assistant to a federal judge. During the past 30 years he has served as a consultant to, and a director of, over 30 private companies and professional, civic, and charitable organizations. Since 1990 he has been a director of the Grafton State Bank, a subsidiary of Merchants & Manufacturers Bancorporation (symbol: MMBI). Among other publicly registered firms on whose boards he serves are Harp & Eagle, Ltd. (symbol: HARP) and Mentor Capital Consultants, Inc. (symbol: MCAP). He also served for a number of years as a director of Mental Health of Ozaukee County, Inc., a non-profit organization promoting mental health and care for the mentally ill. Mr. Kranitz earned his B.S. degree from the University of Wisconsin - Milwaukee and his J.D. degree from the University of Wisconsin - Madison.


http://www.genomedics.com/index.cfm?action=directors

Management

David W. Moskowitz, MD, MA(Oxon.), FACP
President, CEO, Chairman and Chief Medical Officer




David W. Moskowitz, MD, MA(Oxon.), FACP- Chairman and Chief Medical Officer
Dr. Moskowitz majored in Chemistry (summa cum laude) at Harvard College, Biochemistry (first class honours) at Merton College, Oxford, and received an MD (cum laude) from the Harvard-MIT Division in Health Sciences and Technology (Harvard Medical School). He trained for 7 years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis, before spending 11 years on the faculty of St. Louis University School of Medicine. Since 1994, Dr. Moskowitz has experienced at first hand the clinical effectiveness of knowing a disease-associated gene (the angiotensin converting enzyme, or ACE, gene). Dr. Moskowitz is a pioneer in the field of medical genomics, and has been recognized for his ground breaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension and type II diabetes.

--------------------------------------------------------------------------------

Paula Hempen, PhD
Chief Scientific Officer




Dr. Hempen has extensive research experience in cancer genetics, the regulation of gene transcription, immunology, and genomics. Dr. Hempen spent the last three years in the laboratory of Dr. Scott Kern at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland. Dr. Hempen's research at Hopkins led to the discovery of two new tumor suppressor genes in pancreatic cancer. Her findings have recently been published.

--------------------------------------------------------------------------------

Robyn L. Owens
CFO




Robyn L. Owens has over twenty years' experience in the health care industry, she has worked on both the payor and the providers side. Her experience includes claims customer service and educating new providers in managed care. She negotiated physician and hospital contracts for Group Health Plan, a large HMO in St. Louis. She educated providers about documentation requirements to increase revenue as a Reimbursement Specialist for Spectrum, the administrator for OCHAMPUS. OCHAMPUS is the healthcare system for tens of millions of military dependents worldwide. Most recently, she negotiated managed care contracts for a network of physical therapy providers, including SSM Healthcare. She is a member of Group Health Association of America, Medical Group Managers Association, and National Association of Female Executives.

--------------------------------------------------------------------------------

Ali Raza Awan
Chief Bioinformaticist




Ali Raza Awan is a graduate of Stanford University. After completing his Bachelor's degree (majoring in Biological Sciences, minoring in Computer Science) with distinction, his interest in the interface between biology and computer science led him to a Master's degree in Bioinformatics, also at Stanford.

Ali has programmed bioinformatics projects in Perl and Java for data mining and pattern discovery. His work has also invovled extensive application of internet technology including HTML, CSS, CGI, XML, and SQL for database development and maintenance. On the purely biological side, his projects have included carrying out genetic screens on C. elegans to isolate innate immunity mutations, and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse heterokaryons.

Company Profile

About Us
GenoMed is a Next Generation DMtm company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics--the study of which genes cause disease--into clinical practice. We combine biotechnology with Disease Management (DM). We develop new and better drugs, we use existing drugs for new disease indications, and we uncover disease before symptoms arise. By studying disease genes, we hope to make medicine more proactive and disease prevention more effective.

What We Do


Drug discovery: Once GenoMed identifies a disease gene without any existing therapy, the company pursues strategic alliances with large, research-oriented pharmaceutical companies to develop new drugs against the target.

Using existing drugs for new clinical indications: Occasionally, knowing a disease gene can make an existing drug more effective. For example, GenoMed has demonstrated that a proprietary regimen of an existing ACE inhibitor can dramatically delay the progression of end-stage kidney disease due to Type 2 diabetes or hypertension in both African American and Caucasian men, as well as the progression of peripheral vascular disease, and even emphysema. This is the first time an ACE inhibitor has been found to be useful for emphysema.

Gene-based diagnostic tests: Knowing the genes which cause a disease allows a physician to diagnose that disease before symptoms ever become visible. In clinical medicine, the earlier the diagnosis, the better the clinical outcome.
Competitive Position
Like the science of genomic medicine, GenoMed takes a targeted and efficient approach to finding and commercializing disease genes. Our past experience in medical genomics has helped us to identify a class of single nucleotide polymorphisms (SNPs) that we believe has strong associations with all common diseases. We use the least expensive, fastest throughput genotyping currently available in the world. Our ability to move much more quickly than larger, more bureaucratic corporations maximizes our intellectual property produced per dollar spent.

History
GenoMed was inspired by Dr. David Moskowitz's research on the angiotensin I-converting enzyme (ACE) gene during the mid 1990s. His lab discovered that ACE was a "master" disease gene. ACE was found to be associated with about 160 common, serious diseases such as type 2 diabetes, common cancers (except for prostate and breast), and psychiatric diseases. Moskowitz, a nephrologist, treated 1,000 of his own patients based on his knowledge of diseases caused in part by ACE. His early efforts produced dramatic results -- the rate of progression of kidney disease due to high blood pressure was reduced by an average of 300% in both African American and Caucasian male patients. Through this new treatment, patients who normally reached dialysis in 4 years were not predicted to reach end-stage kidney disease for 16 years. Patient outcomes for kidney failure due to type 2 diabetes, atherosclerotic peripheral vascular disease, and emphysema (COPD) were equally exciting. In February 2001 Moskowitz founded GenoMed with the help of industry veterans Jerry White, Richard Kranitz and Peter Brooks.



Code of Ethics
It is the policy of GenoMed, Inc. (the "Company") that the Company's Chief Executive Officer, Chief Financial Officer, principal accounting officer and controller (or persons performing similar functions) adhere to, advocate and promote the following principles:

Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
Full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the "SEC") and other public Compliance with laws, rules and regulations applicable to the Company.
Reporting and Treatment of Violations
Persons who become aware of suspected violations of this Code should report such suspected violations promptly to the Chairman or Secretary of the Company's Board of Directors. To assist in the response to or investigation of the alleged violation, the report should contain as much specific information as possible to allow for proper assessment of the nature, extent and urgency of the alleged violation. Without limiting the foregoing, the report should, to the extent possible, contain the following information:

the alleged event, matter or issue that is the subject of the alleged violation;
the name of each person involved;
if the alleged violation involves a specific event or events, the approximate date and location of each event; and
any additional information, documentation or other evidence available relating to the alleged violation.
The Board of Directors or any committee thereof subsequently created for the purpose of managing alleged violations of the Code of Ethics shall have the power to monitor, investigate, make determinations and recommend action to the Board of Directors with respect to violations of this Code. In determining whether a violation of this Code has occurred, the following may be taken into account:

the nature and severity of the violation;
whether the violation was a single occurrence or involved repeated occurrences;
whether the violation appears to have been intentional or inadvertent;
whether the person in question had been advised prior to the violation as to the proper course of action;
whether the person in question had committed other violations in the past; and
such other facts and circumstances as the Audit Committee shall deem advisable in the context of the alleged violation.
Consequences of Violations
If a violation is substantiated, the Board of Directors, may impose such sanctions or take such actions as it deems appropriate, including, but not limited to, the following:

Disciplinary action (including censure, re-assignment, demotion, suspension or termination);
Pursuit of any and all remedies available to the Company for any damages or harm resulting from a violation, including injunctive relief; and
Referral of matters to appropriate legal or regulatory authorities for investigation and prosecution.
Requests for Waivers and Changes in Code
A waiver of a provision of this Code shall be requested whenever there is reasonable likelihood that a contemplated action will violate the Code. Any waiver (including an implicit waiver) that constitutes a material departure from a provision of this Code shall be publicly disclosed on a timely basis, to the extent required by applicable rules and regulations of the SEC. In addition, any amendments to this Code (other than technical, administrative or other non-substantive amendments) shall be publicly disclosed on a timely basis, to the extent required by applicable rules and regulations of the SEC.

http://www.genomedics.com/index.cfm?action=company

Targeted Diseases (nothing about Marburg or Ebola here)


Diseases with Published Superior Clinical Outcomes:

Kidney failure due to type 2 ("adult onset") diabetes (ref. #1)

Kidney failure due to high blood pressure (ref. #1)

Emphysema ("COPD") (ref. #1)

Poor circulation due to high blood pressure (ref. #1)

Contact GenoMed if you would like information about subscribing to our Clinical Outcomes Improvement Program (COIP®) for one of the above diseases.

Diseases in Clinical Trials:


Cancer (of any organ, any stage, including leukemias and lymphomas)

HIV

SARS

Influenza

Hepatitis (A, B, and C)

Multiple sclerosis

Alopecia

Psoriasis (ref. #6)

Chronic fatigue syndrome/fibromyalgia

Lupus

Rheumatoid Arthritis

Alzheimer's Disease

Parkinson's Disease

ALS ("Lou Gehrig's Disease")

Age-related macular degeneration

Glaucoma

West Nile virus (ref. #6)
Pre-Clinical Research (looking for disease-predisposition genes):
Currently collections are underway or scheduled for the following diseases:

All cancers


GenoMed would be delighted to discuss collaborations with qualified groups that are dedicated to solving specific diseases. Please contact us at dwmoskowitz@genomed.com.

Scientific Advisory Board

Genomed's Advisory Boards
The discovery of disease-causing genes and translation of this knowledge into routine clinical practice will revolutionize medicine. Instead of being hospital-based and largely futile, medicine will become truly effective at prevention of diseases for the first time. To accomplish this transformation will require the best minds in the business. GenoMed recognizes that it will have to rely heavily on the talents of distinguished advisors to accomplish such a transformation. The Company has created two Advisory Boards, one for science and ethics, and the other for business development.

I. Scientific Advisory Board

Chair: David W. Moskowitz MD (physician-scientist who identified angiotensin I-converting enzyme (ACE) as a "master" disease gene; President and CEO of GenoMed; St. Louis, MO)

Sergei Danilov, M.D., Ph.D., Dr.Sci.
Dr. Danilov is one of the half-dozen or so world experts on the angiotensin I-converting enzyme (ACE). Between 1986 and 1993, while Deputy Director of the Cell Biology Department of the National Cardiology Research Center in Moscow, Russia, he developed over a dozen monoclonal antibodies against ACE. He used these antibodies to probe the role of ACE in normal physiology and disease. Dr. Danilov is the author of over 80 journal articles, of which 56 relate to ACE.


Frank Johnson MD
Dr. Johnson is a leading academic surgeon with special expertise in cancer surgery. He is currently Professor of Surgery at St. Louis University School of Medicine, and Chief of Surgery at the St. Louis VA Medical Center.

Dr. Johnson received both his undergraduate degree (with Phi Beta Kappa honors) and his M.D. degree from the University of Minnesota. He then trained in general and oncologic surgery at UCLA, the University of Washington in Seattle, and the University of Colorado in Denver. He spent four years as a Surgical Research Fellow, first at the University of California, San Francisco, and then at the Memorial Sloan-Kettering Cancer Center in New York. His surgical training was interrupted for two years in 1969-71. He spent those two years on active duty as a Navy surgeon, in part with the First Marine Division in DaNang, Vietnam, for which he received the Bronze Star and the Navy Commendation Medal.

Dr. Johnson is the author of over 200 journal articles and a dozen books and book chapters. He has been featured in 14 videos demonstrating advanced surgical techniques, and he received an award for excellence in student teaching for three years in a row at St. Louis University School of Medicine. He is on the editorial boards of 6 surgical journals, and a member of 31 professional societies, including serving as co-founder of the Children�s Heart Fund in Minneapolis, a non-profit organization now known as Children�s Heart Link. As a Visiting Professor supported by the Royal College of Surgeons in 1986-87 and by the Central Surgical Association Foundation in 1995, he has taught at more than a dozen of the finest surgical hospitals in England, Wales, Italy, and the Netherlands. In 1982, he was a Visiting Professor in Brazil. His scientific interests range from the molecular aspects of cancer to the cost of cancer surgery.


Masakazu Kobayashi, Ph.D.
Dr. Kobayashi is the Senior Vice President and Director of Research at Fujisawa Research Institute of America and has been employed with the Institute since 1970. Dr. Kobayashi is considered an expert within the fields of organic chemistry, signal transduction, and immunology.

Dr. Kobayashi received his Ph.D. from Kwansei Gakuin University and diversified his studies into Biochemistry and Immunology at the University of California - Irvine. Dr. Kobayashi was a lecturer in the Neuroscience Department at the University of Okayama in Japan, and has served as an abstract reviewer for the International Society of Transplantation since 1996.


Jason Moore, Ph.D.
Dr. Moore received his training in Applied Statistics (M.A.) and Human Genetics (M.S., Ph.D.) at the University of Michigan with a focus on the genetic epidemiology of common, complex diseases such as hypertension and cardiovascular disease. Now an Assistant Professor in the Program in Genetics at the Norris Cotton Cancer Center in the Dartmouth Medical School, Dr. Moore has established himself as a leader in the development and application of cutting-edge statistical and computational methods for identifying genes that influence the risk of common diseases only through complex interactions with other genes and environmental factors. Dr. Moore recently received the 2001 James V. Neel Young Investigator award from the International Genetic Epidemiology Society in connection with his work in this area. His current work includes the development of the Multifactor Dimensionality Reduction (MDR) approach that was used in the first study to demonstrate interactions between more than three single-nucleotide polymorphisms in a common, complex human disease -- sporadic breast cancer. The development of machine learning and pattern recognition approaches such as MDR and the establishment of a 110-processor supercomputer have positioned Dr. Moore to lead efforts to identify combinations of single-nucleotide polymorphisms from among thousands of candidates in order to better predict the risk of common disease such as hypertension, cardiovascular disease, cancer, depression, and diabetes.


Scott Williams, Ph.D.
Dr. Williams is currently Associate Professor in the Department of Medicine, with appointments in both the Division of Cardiovascular Medicine and the Program in Human Genetics at Vanderbilt University, Nashville, Tennessee.

Dr. Williams is an expert in human genomics who has extensive knowledge of population genetics, genetic epidemiology, molecular genetics, and computing techniques. He has written over 35 articles in the human genomics field which have appeared in various publications, including "Combinations of variations in multiple genes are associated with hypertension," published in the Hypertension Journal during 2000. In 1997, Mr. Williams became Co- Director of Meharry Medical College's Computational Biology Core Facility and began directing a study to find hypertension genes among African American patients, as well as patients from Ghana.


Werner Dubitzky, Ph.D.
Werner Dubitzky received his BSc degree in electrical and communication engineering from the Augsburg University of Applied Science, Germany, in 1991 and his Ph.D. in artificial intelligence and machine learning from the University of Ulster, Northern Ireland, UK, in 1997. From January 2000 to December 2001 he spearheaded the data mining developments at the Intelligent Bioinformatics Systems Group at the German Cancer Research Center, Heidelberg, Germany. Since January 2002 he has held the Chair of Bioinformatics at the School of Biomedical Sciences, Faculty of Life and Health Science, at the University of Ulster at Coleraine, Northern Ireland, UK. He is Head of the Bioinformatics Research Group at the same institute. His current research interests include bioinformatics, systems biology, data and text mining, data warehousing, and grid technology.




A. ELSI Committee


ELSI stands for "Ethical, Legal and Social Implications" and was first coined by the Human Genome Project at the urging of Dr. James Watson. Five percent of funding for the Human Genome Project, which discovered the sequence of the human genome, was set aside for research on the ethical, legal, and social implications of such a discovery. The implications of human genomics were meant to be addressed at the same time as the science. In the same spirit, GenoMed has identified national experts in ethics and health law to help advise the Company on the ethical, cultural, legal, and other social implications of its own research.

Members of the ELSI Committee include the following:

Chair: Dennis A. Robbins PhD, MPH (Founder, Integrated Decisions Ethics, Alternatives and Solutions, Phoenix AZ)

David Sundwall MD (head of American Clinical Laboratory Association, Washington, DC; former Director of the Indian Health Service)

Sylvia Johnson PhD (Director of Healthcare Research, UAW, Detroit, MI)

Sherry Dacso PhD, JD (healthcare lawyer with PhD in genetics, TX)

David W. Moskowitz MD (GenoMed, Inc., St. Louis, MO) ex officio



II. Business Development Advisory Board


GenoMed's Business Development Advisory Board creates the architecture to ensure improved access and availability of genomic technology to the populace. Until now, medicine has battled disease symptoms late in the natural course of chronic diseases without knowing the genetic causes of various diseases, as well as the patient's own genetic predisposition to disease. Knowledge can transform the battle to the patient's advantage, especially when safe, effective treatment can be given before symptoms arise.

Currently, a robust business model for preventive medicine is lacking. Almost by definition, disease prevention takes several years to see a return on investment (ROI). Accordingly, disease prevention is a hard sell to health plans when employer groups and patients switch health plans every few years in search of cheaper premiums. Without prevention, healthcare premiums will continue to skyrocket.

GenoMed's Business Development Advisory Board assists the Company to introduce Next Generation DMTM, which offers financial incentives for physicians to deliver effective, genomics-based preventive medicine.

Committee Members

Chair: Dennis A. Robbins PhD, MPH (Founder, Integrated Decisions Ethics, Alternatives and Solutions, Phoenix AZ)

Joel V. Brill MD (Founder, Predictive Modelling, LLC, American Gastroenterological Association representative to the American Medical Association; expert in coding in reimbursement; Phoenix, AZ)

David W. Moskowitz MD (GenoMed, Inc., St. Louis, MO) ex officio

http://www.genomedics.com/index.cfm?action=advisory

GENOMED INC (Other OTC:GMED.PK) Delayed quote data

Last Trade: 0.065
Trade Time: Apr 26
Change: 0.005 (8.33%)
Prev Close: 0.06
This came off the Yahoo finance site.

Open: 0.057
Bid: N/A
Ask: N/A
1y Target Est: N/A

Day's Range: 0.057 - 0.065
52wk Range: N/A - N/A
Volume: 206,592
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

ANALYST
No analyst data available for GMED.PK.

BUSINESS SUMMARY
No business summary available for GMED.PK

Oh my god.

4-Apr-2005

Annual Report



ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.
Forward-Looking Statements.

The following discussion and analysis contains forward looking statements and should be read in conjunction with our financial statements and related notes. For purposes of this plan of operations, GenoMed, Inc. is referred to herein as "we," "us," or "our." This discussion and analysis contains forward-looking statements based on our current expectations, assumptions, estimates and projections overview. The words or phrases "believe," "expect," "may," "should," "anticipates" or similar expressions are intended to identify "forward-looking statements". Actual results could differ materially from those projected in the forward-looking statements as a result of the following risks and uncertainties, which are more fully discussed in our periodic filings which are available for review at www.sec.gov: (a) during 2004, our Plan of Operations was substantially delayed due to lack of financing b. if we are not awarded patents or licenses, we will never market potential products and our potential revenues will be negatively affected; our business may be adversely affected by regulatory costs which would negatively affect our potential profitability; (d) because our genomics method of gene identification is a relatively new gene identification method, the public or prospective strategic partners may not accept it as an acceptable gene identification method, which would negatively affect our operations and potential revenues; (e) our competitors may develop and respond to gene procedures and products before us due to their superior financial and technical resources and superior technologies; (f) we may be subject to medical or product liability claims that will negatively affect our potential profitability and may lead to losses; (g) because we will lack control over the outsourcing of sample collection, genotyping and data analysis, our quality control and brand name reputation may be negatively affected; (h) if we fail to recruit test patients for our clinical trials, our development of potential products will be delayed which would negatively affect our potential revenues; (i) if our strategic partners fail to obtain Federal Drug Administration approval, our costs may increase and our revenues may decrease; (j) our entire business plan is dependent upon forming strategic alliances or acquisitions or partnership alliances with others for which there are no assurances, and if we fail to do so we will never generate any revenues; (k) if we fail to abide by the terms of our acquisition agreement in which we acquired Genomic Medicine, LLC, the acquisition could be rescinded and we would have no business or ability to generate revenues; (l) if we fail to conduct adequate due diligence regarding our strategic alliances or acquisitions and partnership alliances, we will be subject to increased costs and operational difficulties; (m) our management decisions are made by our President/Chief Executive Officer/Chairman of the Board/ Chief Medical Officer, Dr. David Moskowitz and if we lose his services, our operations will be negatively impacted; (n) we have issued a substantial amount of our common stock in connection with funding that we obtained, which substantially dilutes the value of your shares; and (o) we have a substantial amount of options outstanding, which if exercised, will result in the issuance of shares of our common stock, which will substantially dilute the value of your shares.


PLAN OF OPERATIONS

We have estimated the following expenses totaling $1,703,600 over the next year:

Annual
Type Expenditures Estimated Amount
------------------- ------------------
Salaries $ 600,000
------------------- ------------------
Operating Expenses $ 200,000
------------------- ------------------
Genotyping $ 703,600
------------------- ------------------
Sample
Collection $ 100,000
------------------- ------------------
Marketing $ 100,000
------------------- ------------------
Total $ 1,703,600
==================




We intend to satisfy these estimated total expenditures through our cash as of March 15, 2005 of approximately $302,400 and revenues or a private placement of our equity Securities.

We have made significant changes during 2004 due to an increase in investments. There has been extensive advertising and marketing in general but specifically in the St. Louis area. We have added five full time staff members, three to work on ongoing clinical research, one for marketing and one for finance. We have applied for several additional patents, which has resulted in an increased in expenses, including attorneys fees.

In the next year, we will focus on validating genotyping, as well as continuing to perform screening genotyping for the common cancers such as lung, prostate, colon, breast and pancreas. We also plan to continue processing blood samples from people with diseases of interest, purifying DNA and working on provisional patients. We will market to several possible resources including, providers, employers physicians and individuals. We intend on securing funds through revenues and private placement of equity securities in additional to the current Pierpoint Investissement agreement.

Our goal is to generate $100,000 in revenues from marketing in 2005. To accomplish this goal, we plan to market directly to the following sources:

1. Direct to Practioners- MD, DO family practice residency programs, general internists and clinically oriented medical schools such as Texas Tech University, Health Science Center and University of Kentucky-Lexington
2. Health Plans
3. Direct to Consumers-Atlanta, Chicago, Washington, DC, New York, Los Angeles
4. Indian Tribes

5. Hispanic and African American Patients
6. State Medicaid Offices-Missouri Florida Tennessee
7. Employers
8. Overseas National Health Services

If we have additional expenses that exceed our estimates and we have insufficient funds at the time or we are unable to obtain sufficient financing, then we will be unable to conduct our Plan of Operations, which may negatively impact development of our brand name and reputation. In the event that we do not obtain adequate financing we may have to liquidate our business and undertake any or all of the following actions:

o Sell or dispose of our assets, if any;
o Pay our liabilities in order of priority, if we have available cash to pay such liabilities;
o If any cash remains after we satisfy amounts due to our creditors, distribute any remaining cash to our shareholders in an amount equal to the net market value of our net assets;
o File a Certificate of Dissolution with the State of Florida to dissolve our corporation and close our business;
o Make the appropriate filings with the Securities and Exchange Commission so that we will no longer be required to file periodic and other required reports with the Securities and Exchange Commission, if, in fact, we are a reporting company at that time; and
o Make the appropriate filings with the National Association of Security Dealers to affect a delisting of our common stock, if, in fact, our common stock is trading on the OTC Bulletin Board at that time.

Based upon our current assets, however, we will not have the ability to distribute any cash to our shareholders. If we have any liabilities that we are unable to satisfy and we qualify for protection under the U.S. Bankruptcy Code, we may voluntarily file for reorganization under Chapter 11 or liquidation under Chapter 7. Our creditors may also file a Chapter 7 or Chapter 11 bankruptcy action against us. If our creditors or we file for Chapter 7 or Chapter 11 bankruptcy, our creditors will take priority over our shareholders. If we fail to file for bankruptcy under Chapter 7 or Chapter 11 and we have creditors, such creditors may institute proceedings against us seeking forfeiture of our assets, if any.

We do not know and cannot determine which, if any, of these actions we will be forced to take.

If any of these foregoing events occur, you could lose your entire investment in our shares.

Liquidity and Capital Resources

Cash at December 31, 2004 amounted to $522,371. We have experienced significant losses from our operations. For the period ended December 31, 2004, we incurred a net loss of $4,271.293. For the period from our inception at January 3, 2001 to December 31, 2004, we incurred a net loss of $7,668,722.


http://biz.yahoo.com/e/050404/gmed.pk10ksb.html

http://finance.yahoo.com/q/bc?s=GMED.PK

I sent this information to a newspaper. I sure hope they pick this story up and check out this company. I wonder how many other company's are out there like this one?

Here is another press release from these guys.

GenoMed Finds Thousands of Cancer-Associated Genotypes
06 Mar 2005



GenoMed, Inc (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has found thousands of cancer-associated genotypes. When placed on GenoMed's HealthChip ™, these genotypes will have the potential to serve as an early warning system for the top six common cancers: breast, colon, lung, ovarian, pancreatic, and prostate. Many of the genes involved are expected to be good drug targets for cancer treatment.

These data were obtained in collaboration with Genome Quebec and represent two-thirds of the single nucleotide polymorphisms (SNPs) in GenoMed's SNPnet™: the "net" of SNPs which GenoMed uses to "fish" for disease genes. GenoMed's SNPnet™ contains 30,000 SNPs. Of the 22,000 SNPs that Genome Quebec has screened so far, about half--a little over 10,000--turned out to have at least a mild association with at least one of the six common cancers above. Nearly 1,500 SNPs had a very strong association with at least one cancer. Three genes had a very strong association with all six cancers and could be excellent drug targets for chemotherapy.

Data from another batch of 8,000 SNPs is pending.

"Our data are as rich as we could have possibly imagined. Our SNPnet™ was well constructed. It will take more time to fully mine all our data. But right off the top, it looks like common diseases are the result of thousands of interacting alleles, not just dozens. Common diseases have very little in common with the single-gene Mendelian diseases that have been discovered so far," said Dr. David Moskowitz, GenoMed's chairman and chief executive officer. "What's exciting is that we may already have enough data to solve the top six cancers--i.e. to be able to predict who will get which cancer, and to suggest more effective treatment for each cancer."

"While it is too soon to predict what impact the identification of these and other genes may have in terms of revenues and earnings, a 1999 article in The Wall Street Journal cited Daniel Cohen as estimating the value of a single disease-linked gene at $40-80 million," Moskowitz added.

About GenoMed

GenoMed is leading the clinical revolution which knowledge of disease genes has already begun. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company also conducts basic research to find genes that cause different diseases and clinical research to test protocols that look promising for improving patient outcomes.

Safe Harbor Statement

This press release contains forward-looking statements pertaining to GenoMed, Inc.'s (The Company's) finances and treatments. The words or phrases "ought to, "should," "could, "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties including, but not limited to: (a) whether subsequent research confirms that the genes we've found are truly linked to common cancers; ( whether Daniel Cohen was right that each disease gene will be worth $40-80 million; and © our research and development being subject to economic, regulatory, governmental and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments unanticipated events or circumstances after the date of such statement.

Contact:
David Moskowitz MD
tel. 314-983-9933
GenoMed, Inc.

http://www.medicalnewstoday.com/medicalnews.php?newsid=20783

GenoMed files gene patents
Medical Patent News
Published: Wednesday, 16-Feb-2005


GenoMed has filed a patent application on two additional genes linked to common cancers. These genes are the third and fourth identified as a result of GenoMed's research in 2005 to date. They have the potential to improve the outcomes for those individuals afflicted with these cancers.
One of the genes is involved in protein transport within the cell. Although there is no drug yet for this gene, GenoMed believes that testing for the presence of the variant could help by identifying cancer at an earlier stage when treatment is more likely to be effective. The gene can also act as a warning sign so individuals who possess this gene variant could be monitored more closely for the development of the cancer.

The second gene is involved in signaling by a well-known hormone. It is possible that clinical trials of this gene could start in the near future. GenoMed is pursuing collaborative agreements with oncologists and their patients in order to start clinical trials. Since the therapy involves an existing drug, the process of conducting trials will be simpler than if a new drug were involved.

"These two additional genes suggest immediate next steps to be taken," said Dr. David Moskowitz, GenoMed chief executive officer and chief medical officer. "We will be making an effort to replicate the results we've achieved with a larger sample population and beginning to use these genes as early- warning signs. We will identify patients who have this gene and who have some family history of the cancers involved. We believe that they will welcome the opportunity to be monitored for the development of cancers they have a higher- than-normal probability of contracting."

"Our lab continues to identify genes linked to cancer. We soon expect to receive data from testing tens of thousands of genes at a time through our collaboration with Genome Quebec, one of the largest genomics research centers in North America. These data should allow us to identify more genes linked to various diseases over time.

"As we proceed, we believe that greater notice of our work will be taken by both patients and medical professionals. This, in turn should lead to both a greater awareness of our technology and an acceleration of the development of GenoMed as a company. While it is too soon to predict what impact the identification of these and other genes may have in terms of revenues and earnings, a 1999 article in The Wall Street Journal cited Daniel Cohen as estimating the value of a single disease-linked gene at $40-80 million" Moskowitz added.

http://www.genomedics.com/


http://www.news-medical.net/?id=7807

You would think that they had a HUGE R & D lab and were the leaders in the industry from reading all of their press releases.

GenoMed Offers Treatment to Combat Effects of Smoking


ST. LOUIS, April 7 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company"
or "GenoMed") (Pink Sheets: GMED) a St. Louis, Missouri-based Next Generation
Disease Management company, announced today in response to Peter Jennings'
extremely courageous sharing of his diagnosis of lung cancer with the American
public that it has something to offer him as well as other cigarette smokers.
Cigarette smoking promotes lung cancer and many other cancers, heart
disease, poor circulation, and emphysema. These are the same diseases, which
GenoMed has found to be due to overactivity of angiotensin I-converting enzyme
(ACE). Cigarette smoking likely activates ACE directly. A logical protection
against the effects of cigarette smoking is to block ACE activity with an ACE
inhibitor. GenoMed has already had success with this approach in a woman with
unresectable pancreatic cancer who lived an extra 14 months with a better
appetite.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "There are
60 million Americans who smoke. Not everybody can quit, because it's so
pleasurable and addictive. For those who can't, we would like to do whatever
we can to lower their risk of cigarette-induced disease."
Smokers without high blood pressure or emphysema who want to see if
GenoMed's treatment will protect them, or patients with lung cancer already,
will be entered into a free clinical trial. Patients with emphysema or high
blood pressure, diseases for which GenoMed has already published superior
outcomes, will be charged $67 a month for GenoMed's Disease Management
service.

About GenoMed
GenoMed believes that ACE is the major gene for aging, and has already
been able to prevent kidney failure due to diabetes and hypertension in
whites, blacks and Hispanics; dramatically delay the progression of terminal
emphysema; and see treatment successes for autoimmune diseases, West Nile
virus encephalitis, and cancer. GenoMed has recently found several thousand
genes for the top six solid cancers -- breast, colon, lung, ovarian,
pancreatic, and prostate -- and expects to have new diagnostic tools ready for
clinical trials soon, with new cancer chemotherapy to follow.

Safe Harbor Statement
This press release contains forward-looking statements, including those
statements pertaining to GenoMed, Inc.'s (the Company's) finances and
treatments. The words or phrases "ought to," "should," "could," "may," or
similar expressions are intended to identify "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from those projected in the
forward-looking statements as a result of a number of risks and uncertainties,
including but not limited to our research and development being subject to
economic, regulatory, governmental, and technological factors. Statements made
herein are as of the date of this press release and should not be relied upon
as of any subsequent date. Unless otherwise required by applicable law, we
specifically disclaim any obligation to update any forward-looking statements
to reflect occurrences, developments, unanticipated events or circumstances
after the date of such statement.

http://www.prnewswire.com/cgi-bin/stories....03338566&EDATE=

I have not yet found when this company first got started or who their management staff was affiliated with prior to joining this company.

Our news media really needs to investigate these guys. They are either the best under funded company (going by their press releases) in the U.S. or there may be a serious problem with this company that needs to be explored. Either way the public has a right to know.

I want to know how they convinced the Angolan government to allow them to "help" in Angola. Just what does "help" mean? What did they promise the Angolan government? What did the Angolan government promise them in return? How many employees are on the ground in Angola? What is our government say about this? Can they conduct experiments on the people of Angola without fear of U.S. law? Do we have laws on the books about this? If not, why not? Who are their partners? Are they affiliated with Health Care Company's in the U.S. Have they been targeted the groups mentioned in their Annual report? What kind of human experiments if any have they done?

If anyone checks this thread out during normal hours I hope you can lend a hand investigating this situation.

GenoMed offers treatment for smokers
Missouri-based disease management firm GenoMed has revealed that it will offer ACE inhibitors as a treatment to combat the effects of smoking for smokers unable or unwilling to quit. (Just how do they propose to force smokers to take their medication if they are unwilling to quit?)

8 Apr 2005, 16:27 GMT - Cigarette smoking promotes lung cancer and many other cancers, heart disease, poor circulation, and emphysema. These are the same diseases, which GenoMed has found to be due to overactivity of angiotensin I-converting enzyme (ACE).

A logical protection against the effects of cigarette smoking, the company believes, is to block ACE activity with an ACE inhibitor.

GenoMed has offered to enter smokers without high blood pressure or emphysema who want to see if GenoMed's treatment will protect them, or patients who already have lung cancer, into a free clinical trial. Patients with emphysema or high blood pressure will be charged $67 a month for GenoMed's disease management service.

"There are 60 million Americans who smoke. Not everybody can quit, because it's so pleasurable and addictive. For those who can't, we would like to do whatever we can to lower their risk of cigarette-induced disease," said Dr Moskowitz, GenoMed's CEO and chief medical officer.

http://www.pharmaceutical-business-review....C6-CE9FD2F43497

What do you make of this? It just keeps getting creepier.


Press Release Source: GenoMed, Inc.


GenoMed, Inc. Issues Clarification
Thursday March 31, 6:12 pm ET


ST. LOUIS, March 31 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News) has been advised that one or more Internet websites are recommending the purchase of the Company's stock, and that unsolicited electronic mail has been circulated encouraging the purchase of the Company's stock. The Company is not responsible for, and is unaware of the source of, such Internet activity and makes no comment about the accuracy of such communications. The Company's management does not comment on research reports or rumors concerning the Company's activities or stock price.
ADVERTISEMENT


Safe Harbor Statement

This press release may contain forward looking statements, including those statements pertaining to GenoMed, Inc.'s finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis will continue to be as effective as it has been so far in humans; ( whether our server holds up to increased demand; © our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

--------------------------------------------------------------------------------
Source: GenoMed, Inc.

http://biz.yahoo.com/prnews/050331/cgth068.html?.v=2

Yup, just keeps getting creepier.

GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care
St.Louis -
ST. LOUIS-- GenoMed Inc. -- ("the Company" or "GenoMed") (Pink Sheets: GMED), a St. Louis, Missouri-based Next Generation Disease Management company, announced that its Chairman and CEO, Dr. David Moskowitz, has been invited to speak today at The 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care.

This conference, held outside Washington, DC ( http://www.worldcongress.com/wcls/ccd/index.cfm ), presents the nation's best practices and thought leaders in implementing successful disease management programs that produce positive clinical and financial outcomes. The conference agenda was designed to address the market demands from employers and public purchasers as well as the leading edge programs offered by health care insurers and providers. The agenda highlights legislative trends that impact the adoption and scope of disease management programs including updates from the Centers for Medicaid and Medicare (CMS) on its Chronic Care Improvement Program.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've been invited to this inaugural conference because our business model consists of using genomics to improve public health, and we've been uniquely successful at it so far for diabetes, hypertension, and emphysema, which affect over 85 million Americans."

Continued Dr. Moskowitz, "GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM™ services, GenoMed is also encouraging patients who control their own Health Savings Account or who can afford $67 a month out-of-pocket to sign up themselves for GenoMed's services."

About GenoMed

GenoMed has found what it believes to be the major gene for aging, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see treatment successes for autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers -- breast, colon, lung, ovarian, pancreatic, and prostate -- and expects to have new diagnostic tools ready for clinical trials soon, with new cancer chemotherapy to follow.

Source: GenoMed Inc.

CONTACT: Dr. David Moskowitz of GenoMed, Inc., +1-314-983-9933, or
dwmoskowitz@genomed.com

Web site: http://www.genomedics.com/
http://www.worldcongress.com/wcls/ccd/index.cfm

http://stlouis.dbusinessnews.com/shownews....ype_news=latest

Here is information from the World Congress event. This is one scary event if you care about true healthcare, not just how to profit from it.

The 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care presents the nation's best practices and thought leaders in implementing successful disease management programs that produce positive clinical and financial outcomes. The conference agenda is designed to address the market demands from employers and public purchasers as well as the leading edge programs offered by health care insurers and providers. The agenda will highlight legislative trends that impact the adoption and scope of disease management programs including updates from CMS on the Chronic Care Improvement Program.

At this groundbreaking summit you will:

Create a framework to change employee behavior by understanding programs that improve lifestyle change, adherence, health, satisfaction, and utilization outcomes
Understand the most effective ways of measuring ROI (Return on Investment)
Deliberate with industry experts in an industry debate to identify the best strategies for benchmarking outcomes measurement
Recognize the value of ‘person centered health’ and its impact on the future of disease management
Learn how the Chronic Care Improvement Program is improving beneficiary health and mitigating costs
Identify the most effective predictive modeling strategies that produce a financial return on disease management investments
Hear exciting case studies from employers who have achieved success in their disease management implementations
Investigate the true cost of ill health and make the business case for your disease

Thought Leaders in Attendance:


William Novelli Chief Executive Officer AARP
David Groves Vice President of Corporate Health Management Comerica
Sandra Foote Director Division of Chronic Care Improvement Programs
Centers for Medicare and Medicaid
Al Lewis Executive Director The Disease Management Purchasing Consortium
Stuart Guterman Director, Office of Research Development & Information
Centers for Medicare and Medicaid
Ian Duncan FSA FIA FCIA MAAA PartnerLotter Actuarial Partners, Inc
William Molmen General Counsel Integrated Benefits Institute
Keynote: Gary Christopherson Senior Advisor for the Under Secretary for Health
Veterans Administration
Tom Wilson, Ph.D. President Trajectory Healthcare
Victor J. Strecher, Ph.D., MPH Professor & Director Health Media Research Laboratory University of Michigan Comprehensive Cancer Center
Robert Doherty Senior Vice President Governmental Affairs and Public Policy
American College of Physicians
Keynote:Christobel SeleckyPresident Disease Management Association of America
Chairman: Patricia Salber, MD, MBA Chief Medical Officer Center for Practical Health Reform
President and CEO QuickClinics
Dr. Donald Fetterolf Chief Medical Officer Highmark Blue Cross Blue Shield
A. Michael Collins PhD, Consulting Practice Leader Thomson/Medstat
William Bunn, MD Vice President of Health, Safety and Productivity
International Truck and Engine
David Moskowitz Chairman, CEO, and Chief Medical Officer Genomed
Alan Muney Chief Medical Officer Oxford Health Plans

Corporate Profile

World Congress is the producer of The World Health Care Congress, The World Health Care Congress – Europe , The World Health Care Innovation and Technology Congress, and The World Congress Leadership Summit Series. World Congress events convene CEOs and senior executives from all segments of the healthcare industry, with the latest thought leaders and case studies, representing innovative, solution-oriented approaches to make significant advances in healthcare cost and quality.

The World Health Care Congress is the first focused and inclusive conference to determine and to implement solutions for an improved U.S. health care system that focuses on the needs of the nation’s largest employers. The World Health Care Congress will convene the major constituencies in health care including: leading health care purchasers, payers, providers, suppliers, analysts and governmental officials. Delegates will determine actionable goals and feasible implementation strategies for a new healthcare model that is based on value, quality and consumer choice. Yeah right, and I have a bridge that I want to sell you.

The World Health Care Innovation and Technology Congress is a global forum to present best practices in the use of strategy and technology in health care. The event will attract health care industry decision-makers and purchasing authorities from both private and public sectors, and will focus on how the implementation of business strategy and technology enables greater quality, safety, access, and cost effectiveness in health care delivery.

The World Health Care Congress – Europe is dedicated to presenting best practices for improved health care delivery and outcomes in Europe. The Congress brings together CEO, CFO, COO, and CIO executives from key organizations that are advancing health care in Europe: providers, payers, suppliers, policy-makers and health officials. The event stimulates the dialogue between public and private sectors and determines actionable plans to promote efficient and sustainable health systems in Europe.

The World Congress Leadership Summit Series addresses the most cutting edge issues for healthcare executives across a range of industry sectors. Designed to expand on topics discussed at invitation-only summits during the World Health Care Congress, this series offers new perspectives on established methodologies, and details solutions to foster innovation and change. The 2005 Leadership Summit Series will include:

The Leadership Summit on Next Generation Health Benefits for Employers and Payers

The Leadership Summit on Disease Management and Chronic Care for Employers and Public Purchasers

The Leadership Summit on Medicare to Transform Public/Private Alliances

The Leadership Summit on Maximizing Margins in Healthcare Delivery for Providers

The 3rd Annual Leadership Summit on Healthcare Quality and Pay-for-Performance Contracting for Employers, Providers, and Payers

http://www.worldcongress.com/world_congress_corporate.cfm

Does anyone know where to go to find a list of the investors in this company?

http://www.worldcongress.com/whcc/index.cfm

they all show on this site.

The link you provided I had already posted above. This link shows the groups that participated in the World Congress event. I am trying to find who invested in genomed.